Hsbc Holdings PLC Trims Position in Supernus Pharmaceuticals, Inc. $SUPN

Key Points

• Hsbc Holdings PLC significantly reduced its stake in Supernus Pharmaceuticals, selling 180,627 shares to own 47,403 shares, which represents a 79.2% decrease in holdings.
• Insider selling is notable as CFO Timothy C. Dec and CEO Jack A. Khattar have sold significant amounts of stock, with insiders collectively selling 179,606 shares valued at $7,617,005 in the last ninety days.
• Analysts have shown mixed sentiments, with ratings shifting from "hold" to "buy" and a consensus price target of $41.00 for Supernus Pharmaceuticals stock.

Hsbc Holdings PLC lessened its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) by 79.2% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 47,403 shares of the specialty pharmaceutical company's stock after selling 180,627 shares during the period. Hsbc Holdings PLC owned about 0.08% of Supernus Pharmaceuticals worth $1,539,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in Supernus Pharmaceuticals by 3.9% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,563 shares of the specialty pharmaceutical company's stock valued at $1,033,000 after buying an additional 1,083 shares during the period. Two Sigma Advisers LP raised its stake in Supernus Pharmaceuticals by 14.7% during the 4th quarter. Two Sigma Advisers LP now owns 7,800 shares of the specialty pharmaceutical company's stock worth $282,000 after acquiring an additional 1,000 shares in the last quarter. Principal Financial Group Inc. raised its stake in Supernus Pharmaceuticals by 3.2% during the 1st quarter. Principal Financial Group Inc. now owns 306,322 shares of the specialty pharmaceutical company's stock worth $10,032,000 after acquiring an additional 9,590 shares in the last quarter. SG Americas Securities LLC increased its stake in Supernus Pharmaceuticals by 63.6% in the first quarter. SG Americas Securities LLC now owns 17,671 shares of the specialty pharmaceutical company's stock valued at $579,000 after purchasing an additional 6,867 shares during the period. Finally, Quantinno Capital Management LP increased its stake in Supernus Pharmaceuticals by 11.5% in the fourth quarter. Quantinno Capital Management LP now owns 8,401 shares of the specialty pharmaceutical company's stock valued at $304,000 after purchasing an additional 864 shares during the period.

Insider Activity

In related news, Director Bethany Sensenig sold 5,369 shares of the business's stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $42.25, for a total transaction of $226,840.25. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Jack A. Khattar sold 1,000 shares of the company's stock in a transaction dated Monday, August 25th. The shares were sold at an average price of $45.00, for a total transaction of $45,000.00. Following the completion of the sale, the chief executive officer directly owned 1,071,459 shares in the company, valued at $48,215,655. This trade represents a 0.09% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 179,606 shares of company stock valued at $7,617,005 in the last quarter. Insiders own 8.80% of the company's stock.

Analyst Ratings Changes

A number of research analysts have commented on the stock. Piper Sandler lifted their price objective on shares of Supernus Pharmaceuticals from $36.00 to $40.00 and gave the company a "neutral" rating in a research note on Friday. Wall Street Zen upgraded shares of Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Zacks Research upgraded shares of Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 19th. Finally, Cantor Fitzgerald boosted their price target on shares of Supernus Pharmaceuticals from $42.00 to $46.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 6th. Two research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $43.00.

Supernus Pharmaceuticals Stock Performance

SUPN stock traded down $0.40 during trading on Tuesday, reaching $44.72. 383,451 shares of the company were exchanged, compared to its average volume of 637,657. The company has a market cap of $2.51 billion, a P/E ratio of 38.91 and a beta of 0.79. Supernus Pharmaceuticals, Inc. has a 52-week low of $29.16 and a 52-week high of $45.94. The stock's 50 day moving average price is $36.89 and its 200 day moving average price is $33.91.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.